Clinical trials show PXR ligand rifampicin increased SHBG levels, highlighting its role in metabolic health.
Sex hormone-binding globulin (SHBG) is a sex hormone carrier. We aimed to characterize the role of pregnane X receptor (PXR), a major regulator of drug metabolism, in SHBG regulation. Serum SHBG was measured in four clinical trials (n = 61) and expression in in vitro experiments in human 3D hepatocyte spheroids and HepG2 cells. We also analysed previously published chromatin immunoprecipitation sequencing data from cryopreserved human hepatocytes. One-week dosing of PXR ligand rifampicin increased SHBG in all but one healthy volunteer (geometric mean induction 2.0-fold; SHBG concentration 70.5 ± 34.1 nmol/L with rifampicin and 36.1 ± 19.0 nmol/L with control; p < 0.0001; 95% confidence interval of the mean of differences between arms 31.9-42.0). In men, serum total testosterone increased and free androgen index decreased. In 3D human hepatocyte spheroids, rifampicin caused a clear induction of SHBG mRNA, while SPA70, a PXR antagonist, decreased both basal and rifampicin-induced SHBG mRNA expression. Analysis of ChIP-sequencing data identified a rifampicin-induced PXR binding site within the SHBG gene. These results show that PXR is a novel regulator of serum SHBG in humans. This mechanism may mediate effects of PXR-activating drugs and other chemicals on sex hormone balance and have implications for metabolic health.
No takes yet. Share an insight, caveat, or question.
Ahonen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: